Galenica stays the course with sales growth

Galenica AG announces growth of 4.8% in its turnover, reaching CHF 1,255.5 million for the first four months of 2024. The Swiss pharmaceutical market contributed to this growth, which benefited from an additional day of sales and increased demand for generics and biosimilars.

Measures promoting the use of generics have made it possible to increase the substitution rate from 75.2% to 80.5%. Galenica pharmacies saw strong demand for medicines and a significant increase in demand for vaccines, excluding COVID-19, which increased by 43%.

The “Logistics & IT” segment saw an increase of 5.6%, with strong growth in the doctors segment and the success of several major technological projects. Galenica confirms its growth outlook for 2024, with an EBIT forecast increasing between 8% and 11%.